KLK3 and prostate carcinoma: A recent case series12 demonstrated a prostate cancer incidence of 14 cases per 10 000 transgender women, which is higher than in previously published data, and reported a higher incidence of aggressive disease among transgender women receiving hormone therapy due to possible diagnostic delay from the misinterpretation of PSA values in the setting of suppressive effects of estrogen.